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Abstract 
Background:  With increasing access to legal cannabis across the globe, it is imperative to more 
closely study its behavioral and physiological effects.  Furthermore, with the proliferation of 
cannabis use, modes of consumption are changing, with edible formulations becoming 
increasingly popular.  Nevertheless, there are relatively few animal models of self-administration 
of the primary psychoactive component of cannabis, ∆9-tetrahydrocannabinol (THC), and almost 
all incorporate routes of administration other than those used by humans.  The aim of the current 
study was to develop a model of edible THC self-administration and assess its impact on CB1 
receptor-mediated behaviors in female and male mice. 
Methods:  Mice were given limited access to a palatable dough which occasionally contained 
THC in doses ranging from 1 to 10 mg/kg.  Following dough consumption, mice were assessed 
for home cage locomotor activity, body temperature, or analgesia.  Locomotor activity was also 
assessed in conjunction with the CB1 receptor antagonist SR141716A. 
Results:  Dough was well-consumed, but consumption decreased at the highest THC 
concentrations.  Edible THC produced dose-dependent decreases in locomotor activity and body 
temperature in both sexes, and these effects were more pronounced in male mice.  
Hypolocomotion induced by edible THC was attenuated by SR141716A, indicating mediation by 
CB1 receptor activation. 
Conclusions:  In contrast to other cannabinoid self-administration models, edible THC is 
relatively low in stress and uses a route of administration analogous to one used by humans.  
Potential applications include chronic THC self-administration, determining THC 
reward/reinforcement, and investigating consequences of oral THC use. 
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1.  Introduction 
Cannabis has been used by humans for centuries (Russo, 2007), and in the United States, 
cannabis and cannabis preparations are the most frequently used illicit drugs among adolescents 
and young adults (Schulenberg et al., 2017).  Although the cannabis plant contains numerous 
phytocannabinoids, its psychoactive effects are primarily due to ∆9-tetrahydrocannabinol (THC) 
(Grotenhermen, 2003; Ranganathan and D’Souza, 2006).  Recently there has been a trend 
towards legalization for both medicinal and recreational purposes, leading to an abundance of 
cannabis-based products, many of which are relatively high in THC concentration compared to 
cannabis plant material.  A particular area of interest is the increase in popularity of THC edibles, 
especially given evidence that this route of administration can elicit extreme, adverse reactions 
(Benjamin and Fossler, 2016; Bui et al., 2015; Favrat et al., 2005; Monte et al., 2015). 
Human research into the effects of cannabis use is limited by both ethical barriers and a 
lack of control over subjects’ prior exposure to cannabis and other drugs.  Therefore, animal 
models of cannabis administration are extremely valuable for the well-controlled investigation of 
behavioral and physiological causes and consequences of cannabis use.  However, self-
administration of cannabinoids in animals has been notoriously difficult to establish (Justinova et 
al., 2005; Melis et al., 2017; Panagis et al., 2008; Tanda and Goldberg, 2003; Wakeford et al., 
2017).  Animal studies successfully demonstrating cannabinoid self-administration typically use 
intravenous delivery (Justinova et al., 2003; Melis et al., 2017; Spencer et al., 2018; Wakeford et 
al., 2017), a route not used by humans and one requiring invasive surgery.  Moreover, successful 
intravenous self-administration often involves food deprivation, restraint, and/or prior exposure 
to experimenter-administered cannabinoids (Fattore et al., 2001; Justinova et al., 2003; 
Martellotta et al., 1998; Melis et al., 2017; Spencer et al., 2018; Wakeford et al., 2017).  
  
Conversely, experimenter administration of cannabinoids has several drawbacks, including the 
stress associated with administration, routes of administration not used by humans, and its 
involuntary nature.  Considering the increase in oral use of THC by humans and the limitations 
of current animal models, two recent studies have had explored oral self-administration of THC 
in rats using cookies (Nelson et al., 2018) or sweetened solutions (Barrus et al., 2018).  In this 
study, we sought to develop a mouse model of THC self-administration with the following aims: 
voluntary oral self-administration in mice of a behaviorally-effective dose(s), repeated self-
administration of a behaviorally-effective dose(s), and CB1 receptor mediation of behavioral 
effects.  We also sought to explore potential sex differences using this model. 
 
2.  Methods 
2.1.  Animals 
 C57BL/6J (B6) mice were obtained from Jackson Laboratory (Bar Harbor, ME) at 7-8 
weeks of age, and experimentation began at 8-9 weeks of age.  All mice had ad libitum access to 
food and water for the duration of the experiment, except for the dough access period (see 
procedure).  Mice were single-housed (Experiments 1 and 3) or pair-housed (Experiment 2) 
under a 12-hour, reverse light/dark schedule in temperature- and humidity-controlled rooms.  
Procedures were approved by the IUPUI School of Science Institutional Animal Care and Use 
Committee and conformed to the Guide for the Care and Use of Laboratory Animals (The 
National Academic Press, 2003). 
2.2.  Drugs 
 THC was provided by the National Institute on Drug Abuse (Bethesda, MD) dissolved in 
95% ethanol at a concentration of 100 mg/ml.  SR141716A (Rimonabant) was purchased from
 1Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi: 
Cayman Chemical (Ann Arbor, MI) and dissolved in 100% ethanol at a concentration of 20 
mg/ml.  The SR141716A-ethanol solution was mixed in a vehicle of Tween-20 and saline in a 
ratio of 1:1:18.  The control vehicle contained an equal amount of ethanol without SR141716A.   
2.3.  Edible Dough 
 Edible dough consisted of flour, sugar, salt, and glycerol (all commercially available).  A 
unique batch of dough was prepared daily for each THC dose to be provided, from which 
individual servings (5 mg per 1 g of body weight) were portioned per mouse.  Mice were moved 
individually from their home cage to an empty cage containing a single dough serving at 1 hour 
into the dark portion of the light/dark cycle, and allowed to consume dough for 180 minutes (day 
1, Experiments 1-3), 90 minutes (day 2, Experiments 1-2), 60 minutes (day 2, Experiment 3), or 
30 minutes (all other days).  Details of dough preparation and access are provided in figure S11.   
2.4.  Experiment 1 
The impact of gradually-increasing (Fade) doses or a fixed (No Fade) dose of edible THC 
on locomotor activity was assessed within subjects in single-housed mice.  Mice were randomly 
assigned to either the THC Fade or No Fade condition (female (n = 8) and male (n = 8) per 
condition).  Following 4 days of introduction to control dough, mice in the Fade condition were 
given alternating access to control and THC dough, with THC dose increasing across access 
periods (1, 1, 2, 2, 5, 5, 5 mg/kg).  Mice in the No Fade condition continued to receive access to 
control dough until a behaviorally effective dose (i.e. 5 mg/kg) was found in Fade mice.  
Timelines of daily dough/dose available and amount of dough consumed in each condition for 
both female and male mice are provided in figures 1A-B and 2A-B, respectively.  Immediately 
following dough access, mice were returned to their home cages, and locomotor activity was 
recorded for the following 23 hours.  Details on the activity monitors used (Columbus
  
 Instruments Inc., Columbus, OH) have been previously published (Linsenbardt and Boehm, 
2012).  On the final day of testing, all mice were given access to 10 mg/kg THC dough.  
Immediately following dough access and prior to replacement in the home cage, mice were 
administered the CB1 receptor antagonist, SR141716A (10 mg/kg), or vehicle at a volume of 
0.01 ml/g (i.p.).  For Experiment 1, for each THC dose, control dough activity was averaged per 
mouse across proximal days (e.g. days 5, 9, 11 (1 mg/kg)).  For SR141716A/vehicle assessment, 
mice were split into low- (THC < 4 mg/kg) and high- (THC > 4 mg/kg) consuming groups.  
Daily activity, relative activity (% of proximal control), dose x activity relationships, and relative 
activity following SR141716A/vehicle treatment were analyzed using repeated measures two-
way ANOVAs followed by Bonferroni-corrected t-tests, Wilcoxon signed rank tests, Pearson 
correlations, and independent-samples t-tests, respectively.   
2.5.  Experiment 2 
The impact of gradually-increasing (Fade) doses of edible THC on body temperature was 
assessed within subjects in pair-housed mice.  Subsequently, the impact of a larger edible THC 
dose on analgesia was assessed between subjects.  Mice (female (n = 8), male (n = 8)) were 
assigned to the Fade condition as described in Experiment 1, with the exception of 2, instead of 
3, days of access to 5 mg/kg THC dough.  Timelines of daily dough/dose available and amount 
of dough consumed for both female and male mice are provided in figures 1C and 2C, 
respectively.  Rectal temperature (°C) of mice was assessed at 1 hour post-consumption on 
control dough days and at 30 minutes, 1 hour, and 2 hours post-consumption on THC dough 
days.  Temperature was measured using a thermometer (Physitemp Instruments, Inc., Clifton, 
NJ) equipped with a mouse rectal probe (Braintree Scientific, Inc., Braintree, MA).  On the final 
day of testing, mice were given access to control or 10 mg/kg THC dough and assessed for 
  
analgesia.  Mice were set in a glass beaker on a hot plate at 55.8 ± 0.2 °C and immediately 
removed at the first pain response, jump or paw lick, or after a maximum latency of 25 seconds.  
Both the hot plate temperature and maximum latency used were within the range of previously 
reported values (Schreiber et al., 1999; Welch and Stevens, 1992).  Analgesia was assessed on 
consecutive days, 1 hour after control dough access on the first day (pre-treatment) and then 1 
and 2 hours after control or 10 mg/kg THC dough access on the second day (post-treatment).  
Analgesia was determined as the percent maximum possible effect (% MPE) using the formula 
% MPE = ((post-treatment latency – pre-treatment latency) / (maximum latency – pre-treatment 
latency)) x 100, as previously published (Schreiber et al., 1999; Welch and Stevens, 1992).  For 
Experiment 2, temperature at 60 minutes post-consumption on the preceding control dough day 
was subtracted from temperatures at 30, 60, and 120 minutes post-consumption on each THC 
dough day.  Within each dose, these temperature differences were collapsed across time points 
and days, as they did not differ significantly based on time point or day for either female, F’s < 
2.51, p’s > .116, or male, F’s < 3.65, p’s > .053, mice.  Due to technical issues with the 
temperature probe, only the first day at 5 mg/kg was included.  Temperature differences were 
analyzed using one-sample t-tests (vs 0°C) as well as Pearson correlations.  The effect of edible 
THC on analgesia was analyzed using repeated measures two-way ANOVAs on %MPE. 
2.6.  Experiment 3 
The impact of a fixed (No Fade) dose of edible THC on body temperature was assessed 
between subjects in single-housed mice (female (n = 24), male (n = 24)).  6 days of access to 
control dough preceded a single test day of access to control, 5 mg/kg, or 10 mg/kg THC dough 
(n’s = 6, 6, 12, respectively per sex).  Timelines of daily dough/dose available and amount of 
dough consumed for both female and male mice are provided in figures 1D and 2D, respectively.  
  
Mice were assessed for rectal temperature (as in Experiment 2) at 2 hours post-consumption on 
the final control dough day and at 1 and 2 hours post-consumption on test day.  All female mice, 
and a randomly-selected subset of male mice (n = 6) with access to 10 mg/kg THC dough, were 
additionally assessed for rectal temperature at 4 and 24 hours post-consumption.  For Experiment 
3, mice were split into control, low- (THC < 5 mg/kg), and high- (THC ≥ 5 mg/kg) consuming 
groups.  Temperature at 2 hours post-consumption on the preceding control dough day was 
subtracted from temperatures at 1, 2, 4, and 24 hours post-consumption on test day and analyzed 
using repeated measures two-way ANOVAs followed by Bonferroni-corrected t-tests, one-
sample t-tests, and Pearson correlations. 
2.7.  Statistical Analysis 
Statistical analysis was conducted in GraphPad Prism 5 (GraphPad Software Inc., La 
Jolla, CA), with significance set at p < .05.  Female and male mice were considered separately, 
except where noted.  Consumption (% of dough consumed) was analyzed separately for each 
experiment and condition (Fade vs No Fade) using Wilcoxon signed rank tests (vs 100%).  
Analyses of individual experiments are described above. 
 
3.  Results 
3.1.  Consumption 
 In female mice, dough was consumed at significantly less than 100% in the Fade 
condition at 5 mg/kg, W = -21, p = .031 (Experiment 1; Fig. 1A; Table 1), and in the No Fade 
condition at control, W = -136, p < .001, and 10 mg/kg, W = -45, p = .004 (Experiment 3; Fig. 
1D; Table 1).  In male mice, dough was consumed at significantly less than 100% in the Fade 
condition at 5 mg/kg, W = -21, p = .031, and 10 mg/kg, W = -28, p = .016 (Experiment 1; Fig. 
  
2A; Table 1), and in the No Fade condition at 10 mg/kg, W = -66, p = .001 (Experiment 3; Fig. 
2D; Table 1).  In all other instances in both sexes, consumption of dough did not differ 
significantly from 100%, W’s > -15, p’s > .058 (Figs. 1A-D, 2A-D; Table 1).  Lastly, 
consumption of dough on the final day of Experiment 2 was not analyzed, as mice were split into 
control and 10 mg/kg groups systematically, based on prior consumption levels. 
3.2.  Experiment 1 
 Daily locomotor activity following consumption of THC dough was compared to that 
following consumption of control dough in 30-minute bins across 8 hours for female and male 
mice in both conditions (Fade and No Fade).  In female Fade mice, there was a main effect of 
time on all days, F’s > 9.40, p’s < .003 (Figs. 3A-C), and an interaction between time and THC 
dose at 1 mg/kg on day 10, F(15, 210) = 6.75, p = .007 (Fig. 3A).  There was a trend towards a 
main effect of THC dose at 2mg/kg on day 12, F(1, 14) = 5.21, p = .057 (Fig. 3B), and a 
significant main effect of THC dose at 5 mg/kg on day 22, F(1, 14) = 4.25, p = .034 (Fig. 3C), 
with THC dough decreasing locomotor activity vs control dough.  In female No Fade mice, one 
mouse was excluded as an outlier with consistently elevated activity, and interestingly at the 5 
mg/kg THC dose, there was a main effect of time, F(15, 180) = 7.16, p = .038, but no main effect 
of THC dose or interaction, p’s > .317 (Fig. 3D).  In male Fade mice, there was also a main 
effect of time on all days, F’s > 36.56, p’s < .001 (Figs. 4A-C).  At 5 mg/kg, there was both a 
main effect of THC dose and interaction between time and THC dose on day 18, F’s > 5.44, p’s 
< .015, with THC significantly decreasing activity at 60, 90, 120, and 180 minutes post-
consumption, p’s < .05, as well as a trend towards a main effect of THC dose on days 22 and 24, 
F’s > 2.60, p’s < .068 (Fig. 4C).  In male No Fade mice, all effects were significant at 5 mg/kg 
on day 24, F’s > 11.96, p’s < .001, with robust decreases in activity following consumption of 
  
THC dough vs control dough for the first 150 minutes following consumption, p’s < .001 (Fig. 
4D). 
To compare sexes, the effect of edible THC on relative locomotor activity (% of proximal 
control dough days) was also assessed, collapsed on days within each THC dose, using expanded 
temporal windows (2-hour bins), and using only mice consuming ≥ 50% of the dose provided.  
There was no effect in either sex at the 1 mg/kg dose, p’s > .127 (Fig. 5A).  At the 2 mg/kg dose, 
edible THC decreased activity in female mice at all time points except 3-4 hours post-
consumption, W’s < -81,  p’s < .019; however, there was no effect in male mice, p’s > .365 (Fig. 
5B).  In Fade mice at 5 mg/kg, edible THC decreased activity in both sexes, lasting 6 hours in 
female mice, W’s < -154,  p’s < .013, and lasting all 8 hours in male mice, W’s < -136,  p’s < 
.033 (Fig. 5C).  In No Fade mice at 5 mg/kg, edible THC decreased activity in both sexes, lasting 
2 hours in female mice, W = -24,  p = .047, and lasting 4 hours in male mice, W’s < -35,  p’s < 
.008 (Fig 5D). 
 In support of THC being responsible for decreases in locomotor activity, THC dose 
consumed was significantly negatively associated with relative activity in both sexes, and this 
relationship was more pronounced in male mice (Table 2).  In support of CB1 receptors 
mediating the effect of edible THC on locomotor activity, combining sexes and conditions for 
hours 1-4 post-consumption on day 33 (10 mg/kg), there was a significant negative relationship 
between dose consumed and relative activity following vehicle, r(16) = -.50, p = .0498 (Fig. 6A; 
Table 2), but not SR141716A, r(16) = -.26, p = .321 (Fig. 6B; Table 2), post-treatment.  
Accordingly, high-consuming mice showed reduced relative activity compared to low-
consuming mice following vehicle post-treatment only, t(14) = 2.60, p = .021 (Fig. 6C). 
3.3.  Experiment 2 
  
 The effect of edible THC on both body temperature and analgesia was examined in pair-
housed mice of both sexes.  In female mice, there was no effect of THC on body temperature for 
any dose, p’s > .184 (Fig. 7A) and no relationship between dose consumed and temperature 
difference, p = .252 (Table 2).  In male mice, there was a trend towards an effect of THC on 
body temperature at the 5 mg/kg dose, t(7) = 2.31, p = .054 (Fig. 7B), but no effect at lower 
doses, p’s > .388.  In addition, there was a significant negative relationship between THC dose 
consumed and temperature difference, r(40) = -.34, p = .032 (Table 2).  Regarding analgesia, 
there was no effect of THC or time point, nor an interaction on %MPE in either sex, p’s > .118 
(Fig. 7C). 
3.4.  Experiment 3 
 Experiment 2 revealed no effect of edible THC on analgesia, and a subtle effect of edible 
THC on body temperature at 5 mg/kg, only in male mice.  Given that these mice had multiple 
exposures to THC, potentially inducing some degree of tolerance, the effect of a single acute 
exposure to edible THC at doses up to 10 mg/kg on body temperature was assessed in 
Experiment 3.  Mice were separated into groups based on test day consumption, control dough, 
THC dough < 5 mg/kg, and THC dough ≥ 5 mg/kg.  These groups did not differ in baseline body 
temperature following consumption of control dough on the preceding day, F(2, 42) = .14, p = 
.871, but a sex difference was present, F(1, 42) = 153.50, p < .001 (Fig. 7D).  On test day, in 
female and male mice, there was a main effect of dose, F(2, 63) = 4.71, p = .021 and F(2, 21) = 
5.01, p = .017, respectively, with high-consuming mice differing from control at the 1 hour time 
point, p’s < .01 (Figs. 7E-F).  High-consuming male mice and both low- and high-consuming 
female mice, but not control, showed a non-zero change in temperature at multiple time points, 
t’s > 2.54, p’s < .027 (Fig. 7E-F).  In support of THC being responsible for reductions in 
  
temperature, THC dose consumed was significantly negatively associated with change in 
temperature at both the 1- and 2-hour time points in both sexes, p’s < .009 (Table 2). 
 
4.  Discussion 
 Mice consumed control dough relatively consistently, and THC dough was well-
consumed, with some reduction at higher doses.  Nevertheless, mice consumed THC dough on 
multiple occasions across a range of doses, and multiple mice consumed 100% of THC dough up 
to 10 mg/kg.  Thus, edible THC provides a translationally-valid route of self-administration in 
mice.  Edible THC produced dose-dependent hypolocomotion lasting multiple hours in both 
sexes, an effect attenuated by the CB1 receptor antagonist SR141716A.  Additionally, THC had 
a modest hypothermic effect in male, but not female mice when consumed chronically 
(Experiment 2), and a more pronounced hypothermic effect when administered acutely 
(Experiment 3).  However, it was not found to produce analgesia in either sex.  Taken together, 
oral self-administration of THC reproduced some of the characteristic effects typically seen 
following experimenter-administered CB1 receptor agonists (Lichtman et al., 2001; Little et al., 
1988; McMahon and Koek, 2007). 
 Although cannabinoid self-administration, including THC, has previously been 
demonstrated (Fattore et al., 2001; Justinova et al., 2003; Martellotta et al., 1998; Melis et al., 
2017; Spencer et al., 2018; Wakeford et al., 2017), this study is among the first to do so using an 
oral route of administration and without food deprivation, invasive surgery, restraint, or prior 
cannabinoid exposure.  In this respect, it is in line with demonstrations of oral THC self-
administration in rats (Barrus et al., 2018; Nelson et al., 2018).  However, there are notable 
differences among the three studies, including the species used and the method of ingestion.  
  
Perhaps most notable is the homogenous nature of the THC preparations provided in the current 
study and Barrus et al. (2018), which allowed for post-hoc determination of dose consumed.  
Nevertheless, all three studies demonstrated what appears to be THC-induced conditioned taste 
aversion, and the current study and Nelson et al. (2018) demonstrated an effect of edible THC on 
CB1 receptor-mediated behaviors.  As such, the use of edible THC as described here could 
provide some advantages over other administration methods.  First, besides brief handling, mice 
were minimally stressed, and they showed similar THC dough consumption patterns in single-
housed and group-housed arrangements (Fade - Experiment 1 vs 2).  Stress associated with 
handling or injection is immediately measurable (Meijer et al., 2006) and can have long-lasting 
behavioral and physiological consequences (Renaud et al., 2015; Sandi and Haller, 2015; 
Torregrossa et al., 2012).  Therefore, oral self-administration could be utilized for a low-stress, 
chronic THC dosing paradigm. 
Second, there is growing interest in understanding the consequences of oral THC 
administration, and while there are animal models of oral self-administration for other 
recreational drugs (Horowitz et al., 1977; Rhodes et al., 2005; Samson, 1986), this is among the 
first to report voluntary oral THC self-administration in non-human animals.  For cannabinoids, 
the standard route of oral administration has been gavage (Anderson et al., 1975; Castañeda et 
al., 1991; Mantilla-Plata and Harbison, 1975; Stiglick and Kalant, 1982), which has a number of 
drawbacks, including stress, tissue damage, and lack of oral-mucosal drug exposure (Vandenberg 
et al., 2014; Zhang, 2011).  For these reasons alone, the oral self-administration procedure here 
presents a reasonable alternative to oral gavage, with the caveat that most mice appear unlikely 
to repeatedly self-administer higher doses (i.e. ≥ 10 mg/kg).  Furthermore, it uses a method of 
consumption analogous to that used in humans, namely edible THC. 
  
 Third, oral self-administration could be used to investigate the rewarding and reinforcing 
properties of THC.  The simple fact that mice self-administered THC dough could be seen as 
evidence that it is rewarding.  However, inspection of consumption patterns indicates that THC 
might have been aversive at higher doses, which is best illustrated in Experiment 1 male Fade 
mice on days 17-25.  This consumption pattern suggests that mice can discriminate THC from 
control dough and that something about the 5 mg/kg dose might have been aversive for some 
mice, something that might be augmented by the addition of cannabidiol to THC dough (Russo 
and Guy, 2006; Spencer et al., 2018; Vann et al., 2008).  It could also be that mice find control 
dough rewarding and are willing to experience the subjective effects of THC, up to a point, to 
consume dough.  As THC and the dough itself cannot be disambiguated in this experiment, a 
choice or preference procedure using both control and THC dough will be beneficial in this 
regard.  In addition, demonstration of THC’s rewarding properties via conditioned place 
preference (CPP) has been fraught with difficulty, typically only occurring under specific 
parameters of dose, inter-dose interval, and prior/priming exposure (Melis et al., 2017; Panagis et 
al., 2008; Tanda and Goldberg, 2003).  A combination of self-administration and CPP could 
possibly allow mice to determine (via consumption) and demonstrate (via CPP) doses of edible 
THC that are rewarding.  Lastly, oral self-administration might be less useful than intravenous 
self-administration in determining the reinforcing properties of THC, as it is yet to be determined 
if edible THC could be delivered as reliably following response requirements and what impact 
the delay in onset of effects following oral administration could have.  However, the reinforcing 
properties of access to an edible THC session could be assessed using a runway procedure 
(Ettenberg and Geist, 1993) or by separating response requirements from consumption 
(Czachowski and Samson, 1999)]. 
  
 An important aim of the current study was to explore potential sex differences.  With 
respect to consumption, subsets of female mice were somewhat inconsistent in consuming dough 
early in the experiment, but became more consistent over time.  In addition, consumption of 
dough in female, but not male, mice appears to be affected by the addition of THC on the first 
exposure, prior to experiencing any pharmacologic effects.  This particular sex difference is 
consistent with that seen for consumption of sweetened solutions upon initial addition of THC in 
rats (Barrus et al., 2018).  Therefore, female mice might be more reserved during initial 
exposures to control and THC dough.  With respect to the effects of THC between sexes, a few 
differences are worth noting.  Female mice showed a THC-induced hypolocomotor response at a 
lower dose (2 mg/kg) than male mice, which was longer in duration than seen at higher doses.  
At the 5 mg/kg dose, male mice showed a more pronounced and longer lasting response than 
female mice, especially without prior exposure to lower doses (No Fade).  In addition, male, but 
not female, mice showed a modest hypothermic response to edible THC at 5 mg/kg following 
repeated administration, while both sexes showed a long-lasting hypothermic response to acute 
administration ≥ 5mg/kg.  Sex differences could be due to pharmacokinetics, and considering 
that oral administration results in more variable absorption of THC and greater synthesis of the 
active metabolite 11-hydroxy-THC (Benjamin and Fossler, 2016; Grotenhermen, 2003; Mantilla-
Plata and Harbison, 1975; Nadulski et al., 2005), a time course of THC and 11-hydroxy-THC 
concentrations in plasma and brain following edible THC consumption in both sexes would be 
valuable. 
 One major limitation of the current study was the use of a single, inbred mouse strain, 
and therefore, the generalizability of findings remains to be determined.  B6 mice were chosen 
for their propensity for oral self-administration of psychoactive drugs (Belknap et al., 1993; 
  
Rhodes et al., 2007).  However, B6 mice have been shown to be less sensitive to THC-induced 
hypothermia and analgesia, but not hypolocomotion, than other mouse strains (Onaivi et al., 
1995), which may have contributed to the ability of edible THC to impact locomotor activity at 
lower doses than the other behaviors measured here.  In addition, with the exception of a small 
subset of mice, body temperature and analgesia measures in the current study were taken in the 
range of 30-120 minutes post-consumption, a time frame consistent with peak plasma 
concentrations and peak hypothermic/analgesic effects following orally-administered THC in 
Swiss-Webster mice (Anderson et al., 1975; Mantilla-Plata and Harbison, 1975).  Considering 
that the effects of edible THC on locomotor activity extended for several hours, our other 
measurements may have been taken prior to the optimal time point(s).  However, peak effects on 
body temperature following acute exposure occurred at 1 hour post-consumption, suggesting 
otherwise. 
In conclusion, edible THC presents a viable alternative to other administration procedures 
for cannabinoids in mice and could be beneficial for chronic dosing, investigations of effects of 
oral administration, and determining reward/reinforcement.  Furthermore, preliminary sex 
differences in consumption and consequences of edible THC warrant further exploration. 
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Table 1  Percent of Dough Consumed           
         
Experiment Sex Condition Dose N Median W p   
1 Female Fade Control 8 98.95 -15 .0625  
   1mg/kg 8 94.95 -10 .1250  
   2mg/kg 8 100.00 -6 .2500  
   5mg/kg 8 90.05 -21 .0313 * 
   10mg/kg 8 81.05 -10 .1250  
  No Fade Control 8 98.60 -10 .1250  
   5mg/kg 8 100.00 - -  
 Male Fade Control 8 100.00 -3 .5000  
   1mg/kg 8 100.00 -1 1.0000  
   2mg/kg 8 100.00 - -  
   5mg/kg 8 84.40 -21 .0313 * 
   10mg/kg 8 39.60 -28 .0156 * 
  No Fade Control 8 100.00 -6 .2500  
   5mg/kg 8 100.00 - -  
2 Female Fade Control 8 100.00 -3 .5000  
   1mg/kg 8 79.55 -15 .0625  
   2mg/kg 8 96.20 -10 .1250  
   5mg/kg 8 87.55 -10 .1250  
 Male Fade Control 8 100.00 -6 .2500  
   1mg/kg 8 100.00 -6 .1736  
   2mg/kg 8 100.00 - -  
   5mg/kg 8 85.00 -15 .0579  
3 Female No Fade Control 6 95.01 
-
136 .0005 *** 
   5mg/kg 6 81.67 -6 .2500  
   10mg/kg 12 61.32 -45 .0039 ** 
 Male No Fade Control 6 100.00 -1 1.0000  
   5mg/kg 6 92.02 -10 .1250  
      10mg/kg 12 58.93 -66 .0010 ** 
* p < .05, ** p < .01, *** p < .001 vs 100%      
  
Table 2  Associations with THC Dose Consumed             
         
Experiment Sex Measure Condition Post-Treatment N r p   
1 Female LM (% of Control) 1-2Hr Fade - 64 -.223 .0760  
                               3-4Hr  - 63 -.077 .5492  
                               5-6Hr  - 63 -.283 .0248 * 
                               7-8Hr  - 63 -.064 .6173  
 Male LM (% of Control) 1-2Hr Fade - 64 -.676 < .0001 *** 
                               3-4Hr  - 64 -.400 .0011 ** 
                               5-6Hr  - 62 -.082 .5288  
                               7-8Hr  - 62 -.448 .0003 *** 
 Female 
LM (% of Control) 1-4Hr (Day 
33) Fade/No Fade Vehicle 8 -.451 .2620  
    SR141716A 8 -.241 .5649  
 Male  Fade/No Fade Vehicle 8 -.569 .1406  
    SR141716A 8 -.191 .6509  
 All  Fade/No Fade Vehicle 16 -.498 .0498 * 
    SR141716A 16 -.265 .3214  
2 Female ∆ Temperature (C) Fade - 40 -.185 .2520  
 Male   - 40 -.339 .0324 * 
 All   - 80 -.277 .0127 * 
3 Female ∆ Temperature (C) 1Hr No Fade - 24 -.602 .0019 ** 
  ∆ Temperature (C) 2Hr  - 24 -.709 .0001 *** 
  ∆ Temperature (C) 4Hr  - 24 -.196 .3580  
  ∆ Temperature (C) 24Hr  - 24 .079 .7133  
 Male ∆ Temperature (C) 1Hr No Fade - 24 -.637 .0008 *** 
    ∆ Temperature (C) 2Hr   - 24 -.526 .0082 ** 
Note: Mice with locomotor activity > 3 SD beyond group means were excluded from correlations.   
* p < .05, ** p < .01, *** p < .001       
  
 
Figure Captions 
Figure 1.  Timeline and dough consumption in female mice (mean ± SEM) for A) 
Experiment 1 Fade condition (n = 8), B) Experiment 1 No Fade condition (n = 8), C) 
Experiment 2 Fade condition (n = 8), and D) Experiment 3 No Fade condition (n’s = 6-
12).  % of dough consumed was calculated by subtracting leftover, post-consumption 
dough weight from initial dough serving weight.  Dough access was 60-120 minutes on 
days 1 and 2 and 30 minutes on all other days.  X-axis indicates experimental day and 
THC dose provided in mg (per kg).  Black circles = control dough.  Gray shapes (unique 
per dose) and dashed vertical lines = THC dough.  Black boxes in (C/D) indicate a 
difference in THC dose provided between subjects. 
 
Figure 2.  Timeline and dough consumption in male mice (mean ± SEM) for A) 
Experiment 1 Fade condition (n = 8), B) Experiment 1 No Fade condition (n = 8), C) 
Experiment 2 Fade condition (n = 8), and D) Experiment 3 No Fade condition (n’s = 6-
12).  % of dough consumed was calculated by subtracting leftover, post-consumption 
dough weight from initial dough serving weight.  Dough access was 60-120 minutes on 
days 1 and 2 and 30 minutes on all other days.  X-axis indicates experimental day and 
THC dose provided in mg (per kg).  Black circles = control dough.  Gray shapes (unique 
per dose) and dashed vertical lines = THC dough.  Black boxes in (C/D) indicate a 
difference in THC dose provided between subjects. 
 
Figure 3.  Locomotor (LM) activity for all female mice (mean ± SEM; n’s = 8) in 30-
minute bins for the first 8 hours post-consumption for Experiment 1.  LM activity is 
shown as the daily mean of mice for THC dough as compared to a single average of the 
daily means of mice on proximal days for control dough.  A/B/C) Locomotor activity for 
female mice in Experiment 1 Fade condition at 1, 2, and 5 mg/kg THC doses.  D) 
Locomotor activity for female mice in Experiment 1 No Fade condition at 5 mg/kg THC.  
*p < .05 vs control. 
 
Figure 4.  Locomotor (LM) activity for all male mice (mean ± SEM; n’s = 8) in 30-minute 
bins for the first 8 hours post-consumption for Experiment 1.  LM activity is shown as the 
daily mean of mice for THC dough as compared to a single average of the daily means 
of mice on proximal days for control dough.  A/B/C) Locomotor activity for male mice in 
Experiment 1 Fade condition at 1, 2, and 5 mg/kg THC doses.  D) Locomotor activity for 
male mice in Experiment 1 No Fade condition at 5 mg/kg THC.  *p < .05, **p < .01, ***p 
< .001 vs control. 
 
Figure 5.  Relative locomotor (LM) activity for female and male mice (mean ± SEM; n’s 
= 7-22) in 2-hour bins post-consumption for Experiment 1.  LM activity is included for 
each instance a mouse consumed ≥ 50% of the THC dose provided and is shown as 
the mean % of a single average of the daily means of these mice on proximal days for 
control dough.  Relative LM activity for mice in the Fade condition at A) 1 mg/kg, B) 2 
mg/kg, and C) 5 mg/kg edible THC doses provided, and D) for mice in the No Fade 
condition at a 5 mg/kg edible THC dose provided.  fp < .05, ffp < .01, fffp < .001 vs 100% 
(female), and mp < .05, mmp < .01, mmmp < .001 vs 100% (male). 
 
Figure 6.  Relative locomotor (LM) activity for all mice on day 33 of Experiment 1 for the 
first 4 hours following 10 mg/kg edible THC with SR141716A (10 mg/kg) or vehicle post-
treatment.  A) Association between THC dose consumed and relative locomotor activity 
following vehicle injection or B) following SR141716A injection (open = female; closed = 
male).  C) Relative locomotor activity of low- (THC < 4 mg/kg) and high- (THC > 4 
mg/kg) consuming mice following SR141716A (10 mg/kg) or vehicle post-treatment 
(mean ± SEM; n’s = 7-9), *p < .05 vs low-consuming. 
 
Figure 7.  A/B) Body temperature and C) analgesia for all mice following repeated THC 
consumption in Experiment 2 (mean ± SEM).  Average change in body temperature 
following control dough consumption in A) female or B) male mice in the Fade condition 
provided 1, 2, and 5 mg/kg THC doses (n’s = 8).  C) % MPE across days 31-32 in mice 
in the Fade condition at 60 and 120 minutes following 10 mg/kg THC or control dough 
access (n’s = 4).  D/E/F) Body temperature for all mice following acute THC 
consumption in Experiment 3 (mean ± SEM).  D) Day 8 baseline body temperature 
following control dough consumption, grouped by THC dose consumed the following 
day, and day 9 change in body temperature in control, low- (THC < 5 mg/kg), and high- 
(THC ≥ 5 mg/kg) consuming E) female or F) male mice in the No Fade condition (n’s = 
6-12).  ^^p < .01 vs control; *p < .05, **p < .01, ***p < .001 vs 0°C. 
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Figure S1.  Preparation and serving of edible dough for mice using flour, sugar, salt, 
and glycerol (ratio = 30g : 4g : 1g : 20ml).  A) Dough preparation begins by weighing 
and mixing all dry ingredients, B) followed by measuring and creating a glycerol solution 
using the NIDA-provided THC-ethanol solution (for THC dough) or just ethanol (for 
control dough).  C) After pipetting the glycerol solution onto the dry ingredients, they are 
thoroughly combined by spatula and by hand to create a batch of dough (unique batch 
daily per THC dose) with the goal of uniform THC distribution.  D) A single dough 
serving is portioned for each mouse (5 mg per 1 g body weight) and placed in a clean, 
empty mouse cage.  E) Close-up of a single dough serving (125 mg for a 25 g mouse).  
F) Within the vivarium, mice are transferred to a clean, empty cage with their weight-
adjusted dough serving at approximately 1 hour into the dark cycle (red-light conditions) 
and allowed to consume dough with water available.  Following the access period, mice 
are returned to their home cages, and the amount of uneaten dough is weighed to 
determine actual dough/dose consumed.  The amount of THC in dough was adjusted to 
target THC doses ranging from 1 to 10 mg/kg, leading to ethanol doses of 0.0075 g/kg 
to 0.075 g/kg, per serving.  The amount of ethanol in control dough was adjusted to 
match the amount of ethanol in THC dough provided on the same/following day. 
